{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:34:51Z","timestamp":1771547691914,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03152-4","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:27:39Z","timestamp":1742387259000},"page":"2314-2334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Noninterventional, Cross-Sectional Study to Assess Patient Prostate Cancer Treatment Preferences and Experiences in Europe"],"prefix":"10.1007","volume":"42","author":[{"given":"Emmanuelle","family":"Kaltenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Rodriguez-Leboeuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Cabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mickael","family":"Henry-Szatkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Inceer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Karim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fallara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"3","key":"3152_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3152_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","volume":"157","author":"T Dyba","year":"2021","unstructured":"Dyba T, Randi G, Bray F, et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308\u201347.","journal-title":"Eur J Cancer"},{"key":"3152_CR3","doi-asserted-by":"crossref","unstructured":"Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243\u201362.","DOI":"10.1016\/j.eururo.2020.09.042"},{"issue":"15","key":"3152_CR4","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.purol.2022.07.147","volume":"32","author":"G Ploussard","year":"2022","unstructured":"Ploussard G, Roubaud G, Barret E, et al. French AFU Cancer Committee Guidelines - Update 2022\u20132024: prostate cancer - Management of metastatic disease and castration resistance. Prog Urol. 2022;32(15):1373\u2013419.","journal-title":"Prog Urol"},{"key":"3152_CR5","unstructured":"NICE. Prostate cancer: diagnosis and management. NICE. 2019. https:\/\/www.nice.org.uk\/guidance\/ng131. Accessed Oct 2024."},{"issue":"24","key":"3152_CR6","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532\u201342.","journal-title":"JAMA"},{"issue":"7","key":"3152_CR7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s12325-016-0351-4","volume":"33","author":"AS Merseburger","year":"2016","unstructured":"Merseburger AS, Hupe MC. An update on triptorelin: current thinking on androgen deprivation therapy for prostate cancer. Adv Ther. 2016;33(7):1072\u201393.","journal-title":"Adv Ther"},{"key":"3152_CR8","unstructured":"EMC (electronic medicines compendium). Decapeptyl\u00ae SR 22.5\u00a0mg patient information leaflet. (Revised Mar 2024). https:\/\/www.medicines.org.uk\/emc\/files\/pil.5906.pdf. Accessed Oct 2024."},{"key":"3152_CR9","unstructured":"EMC (electronic medicines compendium). Decapeptyl\u00ae SR 11.25\u00a0mg patient information leaflet. (Revised Mar 2024). https:\/\/www.medicines.org.uk\/emc\/files\/pil.780.pdf. Accessed Oct 2024."},{"key":"3152_CR10","unstructured":"EMC (electronic medicines compendium). Decapeptyl\u00ae SR 3\u00a0mg patient information leaflet. (Revised Mar 2024). https:\/\/www.medicines.org.uk\/emc\/files\/pil.963.pdf. Accessed Oct 2024."},{"issue":"5","key":"3152_CR11","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1007\/s00520-021-06753-1","volume":"30","author":"S Pan","year":"2022","unstructured":"Pan S, Mao J, Wang L, Dai Y, Wang W. Patient participation in treatment decision-making of prostate cancer: a qualitative study. Support Care Cancer. 2022;30(5):4189\u2013200.","journal-title":"Support Care Cancer"},{"issue":"Pt B","key":"3152_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.cct.2015.09.024","volume":"45","author":"R Jayadevappa","year":"2015","unstructured":"Jayadevappa R, Chhatre S, Gallo JJ, et al. Treatment preference and patient centered prostate cancer care: design and rationale. Contemp Clin Trials. 2015;45(Pt B):296\u2013301.","journal-title":"Contemp Clin Trials"},{"key":"3152_CR13","doi-asserted-by":"crossref","unstructured":"Crawford ED, Sartor O, Chu F, et al. A 12-month clinical study of LA-2585 (45.0\u00a0mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006;175(2):533\u20136.","DOI":"10.1016\/S0022-5347(05)00161-8"},{"issue":"12","key":"3152_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2165\/11319690-000000000-00000","volume":"29","author":"EA Lundstrom","year":"2009","unstructured":"Lundstrom EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase\u00a0III study. Clin Drug Investig. 2009;29(12):757\u201365.","journal-title":"Clin Drug Investig"},{"key":"3152_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/CMAR.S12700","volume":"3","author":"ED Crawford","year":"2011","unstructured":"Crawford ED, Phillips JM. Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res. 2011;3:201\u20139.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"3152_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/21681805.2013.820789","volume":"48","author":"M Fode","year":"2014","unstructured":"Fode M, Nielsen TK, Al-Hamadani M, et al. Preferred treatment frequency in patients receiving androgen deprivation therapy for advanced prostate cancer. Scand J Urol. 2014;48(2):183\u20138.","journal-title":"Scand J Urol"},{"key":"3152_CR17","unstructured":"Moneer S, Patch J, Brown L, Sutton L. Patient treatment experience in prostate cancer: findings from a web-based study 39th Annual European Association of Urology Congress (EAU24); 5\u20138 April 2024, Paris, France."},{"key":"3152_CR18","first-page":"419","volume":"7","author":"K Srivastava","year":"2013","unstructured":"Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419\u201334.","journal-title":"Patient Prefer Adherence"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03152-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03152-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03152-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:50:46Z","timestamp":1744872646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03152-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3152"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03152-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patrick Cabri: was an Ipsen employee at the time of manuscript development, but has since retired. Mickael Henry-Szatkowski: IQVIA employee. Mehmet Inceer: IQVIA employee. Emmanuelle Kaltenbach: Ipsen employee. Emma Karim: Ipsen employee. Val\u00e9rie Perrot: Ipsen employee. Ana Maria Rodriguez-Leboeuf: IQVIA employee. Giuseppe Fallara: none. Matteo Ferro: now affiliated with Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, 20142 Milan, Italy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Ethics approval was not required in France or the UK, and there were no ethics committees in Belgium, Italy, or Spain established to review this study, which is considered market research because the data collected are from surveys and\/or interviews and no clinical data were collected. This survey was not designed to report adverse events and\/or product complaints.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}